Atrium Therapeutics Stock (NASDAQ:RNA)

Forecast Revenue Ownership Financials Chart

Previous Close

$13.85

52W Range

$11.95 - $16.77

50D Avg

$13.92

200D Avg

$13.92

Market Cap

$209.30M

Avg Vol (3M)

$968.83K

Beta

-

Div Yield

-

RNA Company Profile

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

511

IPO Date

Feb 27, 2026

Website

RNA Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 25	Dec 24
Reportable Segment	$18.75M	$10.90M

Fiscal year ends in Dec 25 | Currency in USD

RNA Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$18.75M	$10.90M	$9.56M
Operating Income	$-745.94M	$-378.94M	$-235.60M
Net Income	$-684.63M	$-322.30M	$-212.22M
EBITDA	$-745.94M	$-376.16M	$-233.50M
Basic EPS	$-4.97	$-2.89	$-2.91
Diluted EPS	$-4.97	$-2.89	$-2.91

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q3 14Nov 17, 14 | 5:00 PM

Q2 14Aug 12, 14 | 5:00 PM

Q1 14May 20, 14 | 5:00 PM